Overview

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Status:
Completed
Trial end date:
2009-10-28
Target enrollment:
Participant gender:
Summary
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus. Patients will be randomized to one of 6 groups to receive RO4998452 at doses of 2.5mg, 5mg, 10mg, 20mg or 40mg po daily, or placebo daily. Patients pre-treated with stable metformin will continue to take their usual dose of metformin throughout the study.The anticipated time on study treatment is <=3 months
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche